{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:08:42Z","timestamp":1778476122533,"version":"3.51.4"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Artificial intelligence is transforming reproductive medicine by enabling more nuanced and personalized interpretation of key biomarkers such as anti-M\u00fcllerian hormone (AMH) and inhibin B. While AMH is widely adopted for assessing ovarian reserve, inhibin B\u2014an follicle-stimulating hormone (FSH)-dependent marker of follicular activity\u2014has been historically underutilized due to its dynamic nature and lack of standardized assays. In this review, we explore how AI-driven tools can integrate these hormonal signals to improve clinical decision-making. We highlight three representative models: OvaRePred (also known as HerTempo), which predicts ovarian reserve and perimenopausal timing; PCOSt, which enables early screening and phenotyping of polycystic ovary syndrome; and POvaStim, which personalizes gonadotropin dosing by modeling ovarian sensitivity. Collectively, these tools offer new possibilities for individualized fertility management and may help shift reproductive care from reactive treatment toward proactive, data-informed health planning. We also discuss emerging innovations such as cross-platform assay harmonization, point-of-care hormone testing, and longitudinal biomarker modeling. Looking ahead, integration with nutritional interventions, wearable technologies, and genetic or immunologic data could extend these tools beyond assisted reproduction\u2014supporting a broader, AI-enabled ecosystem for women\u2019s lifelong health.<\/jats:p>","DOI":"10.3389\/fendo.2026.1724929","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:28Z","timestamp":1778473408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ovarian intelligence: AI applications leveraging AMH and inhibin B"],"prefix":"10.3389","volume":"17","author":[{"given":"Huiyu","family":"Xu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital)","place":["Beijing, China"]},{"name":"Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology","place":["Beijing, China"]},{"name":"National Clinical Key Specialty Construction Program","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farideh","family":"Bischoff","sequence":"additional","affiliation":[{"name":"HerAnova Lifesciences, Inc.","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital)","place":["Beijing, China"]},{"name":"Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology","place":["Beijing, China"]},{"name":"National Clinical Key Specialty Construction Program","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4137\/bmi.s537","article-title":"Biomarkers of ovarian reserve","volume":"3","author":"Roudebush","year":"2008","journal-title":"biomark Insights"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000459864.68372.ec","article-title":"Committee opinion no. 618: Ovarian reserve testing","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-020-01700-1","article-title":"A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: A retrospective cohort study","volume":"37","author":"Xu","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-008-9241-2","article-title":"Ovarian reserve evaluation: State of the art","volume":"25","author":"de Carvalho","year":"2008","journal-title":"J Assist Reprod Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100091","article-title":"Clinical applications of serum anti-mullerian hormone measurements in both males and females: An update","volume":"2","author":"Xu","year":"2021","journal-title":"Innovation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8545(21)00214-x","article-title":"Characteristics and control of the normal menstrual-cycle","volume":"17","author":"Espey","year":"1990","journal-title":"Obstet Gyn Clin N Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del291","article-title":"Serum anti-mullerian hormone throughout the human menstrual cycle","volume":"21","author":"La Marca","year":"2006","journal-title":"Hum Reprod"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(99)00639-1","article-title":"Serum mullerian-inhibiting substance levels during normal menstrual cycles","volume":"73","author":"Cook","year":"2000","journal-title":"Fertil Sterility"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.mce.2003.09.024","article-title":"Anti-mullerian hormone and its role in ovarian function","volume":"211","author":"Gruijters","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti-mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment","volume":"10","author":"Weenen","year":"2004","journal-title":"Mol Hum Reprod"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmh057","article-title":"Inhibins in female and male reproductive physiology: Role in gametogenesis, conception, implantation and early pregnancy","volume":"11","author":"Luisi","year":"2005","journal-title":"Hum Reprod Update"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/molehr\/gaw070","article-title":"Inhibin-b secretion and fsh isoform distribution may play an integral part of follicular selection in the natural menstrual cycle","volume":"23","author":"Andersen","year":"2017","journal-title":"Mol Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0331","article-title":"Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation","volume":"91","author":"Hehenkamp","year":"2006","journal-title":"J Clin Endocr Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/en.142.11.4891","article-title":"Anti-mullerian hormone attenuates the effects of fsh on follicle development in the mouse ovary","volume":"142","author":"Durlinger","year":"2001","journal-title":"Endocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.12.5614","article-title":"Anti-mullerian hormone and anti-mullerian hormone type-ii receptor messenger-ribonucleic-acid expression during postnatal testis development and in the adult testis of the rat","volume":"136","author":"Baarends","year":"1995","journal-title":"Endocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/me.2013-1082","article-title":"Phosphoinositide 3-kinase p110\u03b4 mediates estrogen- and fsh-stimulated ovarian follicle growth","volume":"27","author":"Li","year":"2013","journal-title":"Mol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00018-024-05251-x","article-title":"P62 promotes fsh-induced antral follicle formation by directing degradation of ubiquitinated wt1","volume":"81","author":"Zhao","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00579","article-title":"Fsh requirements for follicle growth during controlled ovarian stimulation","volume":"34","author":"Hunjan","year":"2019","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/gat024","article-title":"Which follicles make the most anti-mllerian hormone in humans? Evidence for an abrupt decline in amh production at the time of follicle selection","volume":"19","author":"Jeppesen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1515\/cclm-2021-0698","article-title":"Intra- and inter-cycle variability of anti-mullerian hormone (amh) levels in healthy women during non-consecutive menstrual cycles: The bicycle study","volume":"60","author":"Biniasch","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg043","article-title":"Serum anti-mullerian hormone dynamics during controlled ovarian hyperstimulation","volume":"18","author":"Fanchin","year":"2003","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2021.03.021","article-title":"Changes in anti-mullerian hormone after ultrasound guided aspiration and ethanol sclerotic therapy of ovarian cyst","volume":"60","author":"Huang","year":"2021","journal-title":"Taiwan J Obstet Gyne"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep366","article-title":"Comparison of inter- and intra-cycle variability of anti-mullerian hormone and antral follicle counts","volume":"25","author":"van Disseldorp","year":"2010","journal-title":"Hum Reprod"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2023.11.009","article-title":"Concordance of hemoglobin a1c and reproductive hormone levels in menstrual and venous blood","volume":"5","author":"Naseri","year":"2024","journal-title":"F&S Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des194","article-title":"Quantification of anti-mullerian hormone (amh) in dried blood spots: Validation of a minimally invasive method for assessing ovarian reserve","volume":"27","author":"McDade","year":"2012","journal-title":"Hum Reprod"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep210","article-title":"Anti-mullerian hormone (amh): What do we still need to know","volume":"24","author":"La Marca","year":"2009","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2024.100068","article-title":"Ovarepred: Redefing ovarian aging and pioneering the journey towards women\u2019s health management","volume":"2","author":"Xu","year":"2024","journal-title":"Innovation Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.946123","article-title":"An online tool for predicting ovarian reserve based on amh level and age: A retrospective cohort study","volume":"13","author":"Han","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70333-2","article-title":"Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: Comparative study with serum alpha-inhibin and estradiol","volume":"174","author":"Rey","year":"1996","journal-title":"Am J Obstet Gynecology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2076","article-title":"Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome","volume":"91","author":"Pigny","year":"2006","journal-title":"J Clin Endocr Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu043","article-title":"The physiology and clinical utility of anti-mullerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.10.004","article-title":"Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives","volume":"40","author":"Landersoe","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.09.134","article-title":"Testing and interpreting measures of ovarian reserve: A committee opinion","volume":"114","author":"Penzias","year":"2020","journal-title":"Fertil Sterility"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.719029","article-title":"Variation in the measurement of anti-mullerian hormone - what are the laboratory issues","volume":"12","author":"Punchoo","year":"2021","journal-title":"Front Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691432","article-title":"Challenges in measuring amh in the clinical setting","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.4.8636341","article-title":"Measurement of dimeric inhibin b throughout the human menstrual cycle","volume":"81","author":"Groome","year":"1996","journal-title":"J Clin Endocr Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1074347","article-title":"An online tool for predicting ovarian responses in unselected patients using dynamic inhibin b and basal antimullerian hormone levels","volume":"14","author":"Ma","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.881983","article-title":"An online tool using basal or activated ovarian reserve markers to predict the number of oocytes retrieved following controlled ovarian stimulation: A prospective observational cohort study","volume":"13","author":"Han","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.9.2331","article-title":"Serum inhibin b levels measured early during fsh administration for ivf may be of value in predicting the number of oocytes to be retrieved in normal and low responders","volume":"17","author":"Eldar-Geva","year":"2002","journal-title":"Hum Reprod"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100401","article-title":"Povastim: An online tool for directing individualized fsh doses in ovarian stimulation","volume":"4","author":"Xu","year":"2023","journal-title":"Innovation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.6.2163","article-title":"Inhibin a and inhibin b responses to gonadotropin withdrawal depends on stage of follicle development","volume":"84","author":"Welt","year":"1999","journal-title":"J Clin Endocr Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.11.2297","article-title":"Dynamic assays of inhibin b and oestradiol following buserelin acetate administration as predictors of ovarian response in ivf","volume":"15","author":"Ravhon","year":"2000","journal-title":"Hum Reprod"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00452.x","article-title":"Inhibin b and anti-mullerian hormone: Markers of ovarian response in ivf\/icsi patients","volume":"111","author":"Muttukrishna","year":"2004","journal-title":"Bjog-Int J Obstet Gy"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.2.409","article-title":"Inhibin a and inhibin b reflect ovarian function in assisted reproduction but are less useful at predicting outcome","volume":"14","author":"Hall","year":"1999","journal-title":"Hum Reprod"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.6.1391","article-title":"Clinical review-46 - clinical utility of inhibin measurements","volume":"76","author":"Burger","year":"1993","journal-title":"J Clin Endocr Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (pcos)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100490","article-title":"Ovarepred: Online tool for predicting the age of fertility milestones","volume":"4","author":"Xu","year":"2023","journal-title":"Innovation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2023.100030","article-title":"Artificial intelligence for medicine: Progress, challenges, and perspectives","volume":"1","author":"Huang","year":"2023","journal-title":"Innovation Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2196\/19096","article-title":"An ovarian reserve assessment model based on anti-mullerian hormone levels, follicle-stimulating hormone levels, and age: Retrospective cohort study","volume":"22","author":"Xu","year":"2020","journal-title":"J Med Internet Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2025.100120","article-title":"Artificial intelligence for medicine 2025: Navigating the endless frontier","volume":"3","author":"Dai","year":"2025","journal-title":"Innovation Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1658068","article-title":"Ovarepred (hertempo): An enhanced ovarian aging clock for personalized reserve assessment, endocrine age modeling, and predicting reproductive milestones across the female lifecycle","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2025.100135","article-title":"Reaffirming the role of ovarian reserve in fertility assessment: Insights from ovarepred","volume":"3","author":"Xu","year":"2025","journal-title":"Innovation Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6148","article-title":"A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile","volume":"84","author":"Diamanti-Kandarakis","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome","volume":"370","author":"Norman","year":"2007","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00886.x","article-title":"Polycystic ovaries and associated clinical and biochemical features in young women","volume":"51","author":"Michelmore","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/humrep\/det469","article-title":"The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-mullerian hormone","volume":"29","author":"Lauritsen","year":"2014","journal-title":"Hum Reprod"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"B59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE\/ASRM-sponsored 3rd PCOS consensus workshop group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4158\/EP15748.DSC","article-title":"American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome--part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.821368","article-title":"A model for predicting polycystic ovary syndrome using serum AMH, menstrual cycle length, body mass index and serum androstenedione in Chinese reproductive aged population: A retrospective cohort study","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100407","article-title":"Pcost: A non-invasive and cost-effective screening tool for polycystic ovary syndrome","volume":"4","author":"Xu","year":"2023","journal-title":"Innovation"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.11.025","article-title":"Sensitive HPLC-DMS\/MS\/MS method coupled with dispersive magnetic solid phase extraction followed by in situ derivatization for the simultaneous determination of multiplexing androgens and 17-hydroxyprogesterone in human serum and its application to patients with polycystic ovarian syndrome","volume":"538","author":"Zhang","year":"2022","journal-title":"Clin Chim Acta"},{"key":"B65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: A systematic review covering 10 years (2007-2017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrin"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/humupd\/dmm034","article-title":"Predictors of ovarian response: Progress towards individualized treatment in ovulation induction and ovarian stimulation","volume":"14","author":"Fauser","year":"2008","journal-title":"Hum Reprod Update"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: A randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00770-5","article-title":"Perspectives on biomarkers of reproductive aging for fertility and beyond","volume":"4","author":"Wang","year":"2024","journal-title":"Nat Aging"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100560","article-title":"Innovation focus in 2023","volume":"5","year":"2024","journal-title":"Innovation-Amsterdam"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2024.100105","article-title":"Twelve practical recommendations for developing and applying clinical predictive models","volume":"2","author":"Feng","year":"2024","journal-title":"Innovation Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41746-024-01006-x","article-title":"The prospect of artificial intelligence to personalize assisted reproductive technology","volume":"7","author":"Hanassab","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00153","article-title":"The use of estrone-3-glucuronide and pregnanediol-3-glucuronide excretion rates to navigate the continuum of ovarian activity","volume":"6","author":"Blackwell","year":"2018","journal-title":"Front Public Health"},{"key":"B73","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-023-36539-w","article-title":"Validation of urinary reproductive hormone measurements using a novel smartphone connected reader","volume":"13","author":"Pattnaik","year":"2023","journal-title":"Sci Rep-Uk"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00184","article-title":"Pilot evaluation of a new urine progesterone test to confirm ovulation in women using a fertility monitor","volume":"7","author":"Bouchard","year":"2019","journal-title":"Front Public Health"},{"key":"B75","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.59717\/j.xinn-med.2024.100081","article-title":"Circrna-based therapeutics: Current opinions and clinical potential","volume":"2","author":"Tang","year":"2024","journal-title":"Innovation Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2024.100074","article-title":"The rapid development of gene-editing technology is making xenotransplantation increasingly common in clinical practice","volume":"2","author":"Zhang","year":"2024","journal-title":"Innovation Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1604314","article-title":"Editorial: Smart devices for personalized nutrition and healthier lifestyle behavior change","volume":"12","author":"Domingues","year":"2025","journal-title":"Front Nutr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2023.100036","article-title":"The associations of energy adjusted dietary inflammatory index with brain structure and cognitive function","volume":"1","author":"Zheng","year":"2023","journal-title":"Innovation Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15301","article-title":"Amhconverter: An online tool for converting results between the different anti-mullerian hormone assays of Roche Elecsys((R)), Beckman Access, and Kangrun","volume":"11","author":"Xu","year":"2023","journal-title":"PeerJ"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1724929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:29Z","timestamp":1778473409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1724929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":79,"alternative-id":["10.3389\/fendo.2026.1724929"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1724929","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1724929"}}